Trials / Recruiting
RecruitingNCT05620732
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
Efficacy and Safety of Claudin18.2CAR-T in Advanced Pancreatic Cancer and Gastric Carcinoma
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Shenzhen University General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.
Detailed description
The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors. Investigators aim to testify to the safety and efficacy of Claudin18.2CAR-T cells in advanced pancreatic cancer and gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Claudin18.2 CAR-T cells | patients treated with Claudin18.2 CAR-T cells |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2025-10-31
- Completion
- 2028-10-31
- First posted
- 2022-11-17
- Last updated
- 2022-11-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05620732. Inclusion in this directory is not an endorsement.